A Phase 1 interventional study of PegIFN alfa-2b in Malignant Melanoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.
Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 14th largest by enrollment, is one of 3 that started in 2012, is one of 5 in phase 1, and was the 10th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 3
First in 1998; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 36 across the 14 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
42 studies in Melanoma by Merck & Co., Inc: 1 open now, 6 under way, 3 of them phase 3. Of 34 finished, 25 (74%) have results posted.
Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2012, is one of 13 in phase 1, and was the 11th registered.
Merck & Co., Inc’s Melanoma studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing peginterferon alfa-2b in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 42 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete lymphadenectomy. Participants on this study will initially receive PegIFN alfa-2b for 8 weeks (Induction Phase) and then may continue to receive PegIFN alfa-2b (Maintenance Phase) as long as they are experiencing clinical benefit (Up to 252 weeks). The primary hypothesis is that peginterferon alfa-2b administered on a weekly basis is safe and tolerated.
The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
Biological: PegIFN alfa-2b
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase
A DLT was an event (clinical or laboratory) that resulted in a change in the given dose.
Time frame: From first dose to end of induction phase; up to 8 Weeks
Safety: Number of Participants Experiencing Adverse Events (AEs)
An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
Time frame: From first dose through follow-up; up to 265 Weeks
Number of Participants Discontinuing Study Drug Because of AEs
An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
Time frame: From first dose to last dose of treatment; up to 260 Weeks
This study enrolled Japanese participants with Stage II or III malignant melanoma who had undergone surgical resection and lymphadenectomy.
| Milestone | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Started | 9 |
| Completed | 7 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
| Milestone | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Started | 7 |
| Completed | 0 |
| Not completed | 7 |
| Withdrew: Continued drug after regulatory approval | 3 |
| Withdrew: Adverse event | 3 |
| Withdrew: Progressive disease | 1 |
A DLT was an event (clinical or laboratory) that resulted in a change in the given dose.
| Participants | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase | 2 |
An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
| Participants | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Safety: Number of Participants Experiencing Adverse Events (AEs) | 9 |
An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
| Participants | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Number of Participants Discontinuing Study Drug Because of AEs | 5 |
Collected over From first dose through follow-up; up to 265 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Receiving PegIFN Alfa-2b | — | 0/9 (0%) | 9/9 (100%) |
| Event | Participants Receiving PegIFN Alfa-2b |
|---|---|
| PyrexiaGeneral disorders | 9/9 |
| Neutrophil count decreasedInvestigations | 9/9 |
| White blood cell count decreasedInvestigations | 9/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/9 |
| Alanine aminotransferase increasedInvestigations | 8/9 |
| Aspartate aminotransferase increasedInvestigations | 8/9 |
| NauseaGastrointestinal disorders | 6/9 |
| ChillsGeneral disorders | 6/9 |
| Injection site reactionGeneral disorders | 6/9 |
| MalaiseGeneral disorders | 6/9 |
| Age, Continuous(Years) | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Mean | 43.3 ± 13.7 |
| Sex: Female, Male(Participants) | Participants Receiving PegIFN Alfa-2b |
|---|---|
| Female | 4 |
| Male | 5 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2012 to primary completion in Mar 2014, 15 months.
Results were first posted in Feb 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b